{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:23:46Z","timestamp":1762917826754,"version":"3.44.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004836","name":"Danish Council for Independent Research","doi-asserted-by":"publisher","award":["4184-00177"],"award-info":[{"award-number":["4184-00177"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jconrel.2018.02.012","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T12:54:40Z","timestamp":1518180880000},"page":"53-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Macromolecular prodrugs of ribavirin: Polymer backbone defines blood safety, drug release, and efficacy of anti-inflammatory effects"],"prefix":"10.1016","volume":"275","author":[{"given":"Kaja","family":"Zuwala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla F.","family":"Riber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaja Borup","family":"L\u00f8vschall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna H.F.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina","family":"Gajda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Tolstrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9864-321X","authenticated-orcid":false,"given":"Alexander N.","family":"Zelikin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2018.02.012_bb0005","doi-asserted-by":"crossref","first-page":"253ps210","DOI":"10.1126\/scitranslmed.3009872","article-title":"Emerging viral diseases: confronting threats with new technologies","volume":"6","author":"Marston","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0010","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study","volume":"380","author":"Lozano","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2018.02.012_bb0015","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nrd2424","article-title":"The design of drugs for HIV and HCV","volume":"6","author":"De Clercq","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0020","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50\u202fyears","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0025","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1126\/science.aaa3778","article-title":"Combating emerging viral threats","volume":"348","author":"Bekerman","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2018.02.012_bb0030","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/imr.12098","article-title":"Advances in Antiviral vaccine development","volume":"255","author":"Graham","year":"2013","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0035","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev.pharmtox.48.113006.094906","article-title":"Topical microbicides to prevent HIV: clinical drug development challenges","volume":"49","author":"Hendrix","year":"2009","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0040","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nri1848","article-title":"Microbicides and other topical strategies to prevent vaginal transmission of HIV","volume":"6","author":"Lederman","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0045","doi-asserted-by":"crossref","first-page":"517","DOI":"10.3389\/fmicb.2015.00517","article-title":"Broad-spectrum antiviral agents","volume":"6","author":"Zhu","year":"2015","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0050","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrd.2017.33","article-title":"Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond","volume":"16","author":"Boldescu","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0055","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2165\/00003495-199142050-00003","article-title":"The use of interferon-alpha in virus infections","volume":"42","author":"Finter","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.jconrel.2018.02.012_bb0060","doi-asserted-by":"crossref","first-page":"921","DOI":"10.4254\/wjh.v9.i21.921","article-title":"Is the 25-year hepatitis C marathon coming to an end to declare victory?","volume":"9","author":"Ahmed","year":"2017","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0065","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1517\/14656566.2.8.1317","article-title":"Ribavirin - current status of a broad spectrum antiviral agent","volume":"2","author":"Snell","year":"2001","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0070","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/nrd2175","article-title":"Antiviral agents active against influenza A viruses","volume":"5","author":"De Clercq","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0075","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1073\/pnas.1101143108","article-title":"Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis","volume":"108","author":"Hoffmann","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0080","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","article-title":"Nitazoxanide: a first-in-class broad-spectrum antiviral agent","volume":"110","author":"Rossignol","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0085","article-title":"A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses","volume":"6","author":"Zhao","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0090","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0095","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrmicro3475","article-title":"Broad-spectrum antivirals against viral fusion","volume":"13","author":"Vigant","year":"2015","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0100","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.antiviral.2016.07.004","article-title":"Nucleic acid polymers: broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection","volume":"133","author":"Vaillant","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0105","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201700748","article-title":"Macromolecular antiviral agents against Zika, Ebola, SARS, and other pathogenic viruses","volume":"6","author":"Schandock","year":"2017","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0110","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0021-9258(18)72516-7","article-title":"The isolation and crystallization of plant viruses and other protein macro molecules by means of hydrophilic colloids","volume":"144","author":"Cohen","year":"1942","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0115","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3181\/00379727-66-15995P","article-title":"Inhibition of mumps virus multiplication by a polysaccharide","volume":"66","author":"Ginsberg","year":"1947","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0120","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0021-9258(19)52422-X","article-title":"The combination of lysine polypeptides with tobacco mosaic virus","volume":"193","author":"Burger","year":"1951","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0125","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3181\/00379727-76-18588","article-title":"Inhibitory effect of synthetic lysine polypeptides on growth of influenza virus in embryonated eggs","volume":"76","author":"Rubini","year":"1951","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0130","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1128\/jb.87.5.1060-1066.1964","article-title":"Inhibitory effect of heparin on herpes simplex virus","volume":"87","author":"Nahmias","year":"1964","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0135","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1128\/jvi.2.9.878-885.1968","article-title":"Antiviral activity of polyacrylic and polymethacrylic acids. I. Mode of action in vitro","volume":"2","author":"Desomer","year":"1968","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0140","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1126\/science.2452480","article-title":"Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells","volume":"240","author":"Mitsuya","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2018.02.012_bb0145","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1039\/C4PY00624K","article-title":"Macromolecular (pro) drugs in antiviral research","volume":"5","author":"Smith","year":"2014","journal-title":"Polym. Chem."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0150","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1086\/505351","article-title":"Interferon and its inducers\u2014a never-ending story: \u201cold\u201d and \u201cnew\u201d data in a new perspective","volume":"194","author":"De Clercq","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0155","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.antiviral.2011.03.176","article-title":"The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1","volume":"90","author":"Pirrone","year":"2011","journal-title":"Antivir. Res."},{"author":"Starpharma","key":"10.1016\/j.jconrel.2018.02.012_bb0160"},{"key":"10.1016\/j.jconrel.2018.02.012_bb0165","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1071\/CH12295","article-title":"Living radical polymerization by the RAFT process \u2013 a third update","volume":"65","author":"Moad","year":"2012","journal-title":"Aust. J. Chem."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0170","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1021\/ma3001719","article-title":"Atom transfer radical polymerization (ATRP): current status and future perspectives","volume":"45","author":"Matyjaszewski","year":"2012","journal-title":"Macromolecules"},{"key":"10.1016\/j.jconrel.2018.02.012_bb0175","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.antiviral.2010.02.318","article-title":"A highly lipophilic sulfated tetrasaccharide glycoside related to muparfostat (PI-88) exhibits virucidal activity against herpes simplex virus","volume":"86","author":"Ekblad","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0180","doi-asserted-by":"crossref","first-page":"17667","DOI":"10.1073\/pnas.0608803103","article-title":"Polymeric coatings that inactivate both influenza virus and pathogenic bacteria","volume":"103","author":"Haldar","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0185","first-page":"2643","article-title":"Macromolecular prodrugs of ribavirin combat side effects and toxicity with no loss of activity of the drug","volume":"49","author":"Kryger","year":"2013","journal-title":"ChemComm"},{"key":"10.1016\/j.jconrel.2018.02.012_bb0190","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/mabi.201300244","article-title":"Macromolecular prodrugs for controlled delivery of ribavirin","volume":"14","author":"Kryger","year":"2014","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0195","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1039\/C4SC02754J","article-title":"Macromolecular prodrugs of ribavirin: towards a treatment for co-infection with HIV and HCV","volume":"6","author":"Smith","year":"2015","journal-title":"Chem. Sci."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0200","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/adhm.201500841","article-title":"Polyanionic macromolecular prodrugs of ribavirin: antiviral agents with a broad Spectrum of activity","volume":"5","author":"Hinton","year":"2016","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0205","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1021\/acs.molpharmaceut.6b00826","article-title":"Macromolecular prodrugs of ribavirin: structure\u2013function correlation as inhibitors of influenza infectivity","volume":"14","author":"Riber","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0210","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jconrel.2014.09.032","article-title":"Macromolecular (pro)drugs with concurrent direct activity against the hepatitis C virus and inflammation","volume":"196","author":"Wohl","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2018.02.012_bb0215","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/adhm.201400307","article-title":"Highly active macromolecular prodrugs inhibit expression of the hepatitis C virus genome in the host cells","volume":"4","author":"Ruiz-Sanchis","year":"2015","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0220","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1021\/jm010969d","article-title":"Synthesis of new covalently bound kappa-carrageenan-AZT conjugates with improved anti-HIV activities","volume":"45","author":"Vlieghe","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0225","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0026-895X(24)12484-4","article-title":"Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase\/integrase) in the virus replicative cycle","volume":"58","author":"Witvrouw","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0230","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1021\/acs.molpharmaceut.6b00156","article-title":"Triple activity of lamivudine releasing sulfonated polymers against HIV-1","volume":"13","author":"Danial","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0235","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1039\/c0py00406e","article-title":"Overcoming the PEG-addiction: well-defined alternatives to PEG, from structure-property relationships to better defined therapeutics","volume":"2","author":"Barz","year":"2011","journal-title":"Polym. Chem."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0240","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1002\/adhm.201500344","article-title":"Self-immolative linkers literally bridge disulfide chemistry and the realm of thiol-free drugs","volume":"4","author":"Riber","year":"2015","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0245","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.2174\/092986710791556069","article-title":"Overview of anticoagulant activity of sulfated polysaccharides from seaweeds in relation to their structures, focusing on those of green seaweeds","volume":"17","author":"Ciancia","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0250","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1161\/01.CIR.103.24.2994","article-title":"Guide to anticoagulant therapy: heparin: A statement for healthcare professionals from the American Heart Association","volume":"103","author":"Hirsh","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2018.02.012_bb0255","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.1073\/pnas.0608647104","article-title":"Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation","volume":"104","author":"Kannemeier","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0260","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2015.02.005","article-title":"The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy","volume":"91","author":"Sockolosky","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0265","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.addr.2017.06.013","article-title":"Prodrugs in medicinal chemistry and enzyme prodrug therapies","volume":"118","author":"Walther","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0270","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/nchem.2629","article-title":"Materials and methods for delivery of biological drugs","volume":"8","author":"Zelikin","year":"2016","journal-title":"Nat. Chem."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0275","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1021\/acsmacrolett.7b00471","article-title":"Synthetic polymer with a structure-driven hepatic deposition and curative pharmacological activity in hepatic cells","volume":"6","author":"Riber","year":"2017","journal-title":"ACS Macro Lett."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0280","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1021\/ja017168k","article-title":"The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates","volume":"124","author":"Caravan","year":"2002","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0285","doi-asserted-by":"crossref","first-page":"22804","DOI":"10.1074\/jbc.M100575200","article-title":"Crystal structure analysis of warfarin binding to human serum albumin - anatomy of drug site I","volume":"276","author":"Petitpas","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0290","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1155\/2012\/736837","article-title":"Glutathione homeostasis and functions: potential targets for medical interventions","volume":"2012","author":"Lushchak","year":"2012","journal-title":"J. Amino Acids"},{"key":"10.1016\/j.jconrel.2018.02.012_bb0295","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1021\/cr300358b","article-title":"Disulfide-cleavage-triggered chemosensors and their biological applications","volume":"113","author":"Lee","year":"2013","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0300","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0169-409X(02)00179-5","article-title":"Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities","volume":"55","author":"Saito","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0305","doi-asserted-by":"crossref","first-page":"12133","DOI":"10.1021\/acs.chemrev.7b00013","article-title":"Ligand-targeted drug delivery","volume":"117","author":"Srinivasarao","year":"2017","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0310","doi-asserted-by":"crossref","first-page":"14498","DOI":"10.1039\/C4CC04280H","article-title":"Disulfide reshuffling triggers the release of a thiol-free anti-HIV agent to make up fast-acting, potent macromolecular prodrugs","volume":"50","author":"Kock","year":"2014","journal-title":"Chem. Commun."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0315","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/cmdc.200700159","article-title":"Prodrug strategies in anticancer chemotherapy","volume":"3","author":"Kratz","year":"2008","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jconrel.2018.02.012_bb0320","doi-asserted-by":"crossref","first-page":"13693","DOI":"10.1021\/ja036387y","article-title":"Competitive reactions in solutions of poly-L-histidine, calf thymus DNA, and synthetic polyanions: determining the binding constants of polyelectrolytes","volume":"125","author":"Zelikin","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0325","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/adhm.201300637","article-title":"Macromolecular prodrugs of ribavirin: concerted efforts of the carrier and the drug","volume":"3","author":"Smith","year":"2014","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0330","first-page":"889","article-title":"Tools of gene transfer applied to the intracellular delivery of non-nucleic acid polyanionic drugs","volume":"52","author":"Kryger","year":"2016","journal-title":"ChemComm"},{"key":"10.1016\/j.jconrel.2018.02.012_bb0335","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.4049\/jimmunol.153.5.2239","article-title":"Inhibition of lipopolysaccharide and Il-1 but not of Tnf-induced activation of human endothelial-cells by suramin","volume":"153","author":"Strassmann","year":"1994","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2018.02.012_bb0340","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1021\/bm901129x","article-title":"In vitro cytotoxicity of RAFT polymers","volume":"11","author":"Pissuwan","year":"2010","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2018.02.012_bb0345","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1021\/bm2004803","article-title":"Phosphorus-containing polymers: a great opportunity for the biomedical field","volume":"12","author":"Monge","year":"2011","journal-title":"Biomacromolecules"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918300725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365918300725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:33:53Z","timestamp":1759160033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365918300725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":69,"alternative-id":["S0168365918300725"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.02.012","relation":{},"ISSN":["0168-3659"],"issn-type":[{"type":"print","value":"0168-3659"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macromolecular prodrugs of ribavirin: Polymer backbone defines blood safety, drug release, and efficacy of anti-inflammatory effects","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2018.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}